-
1
-
-
84892805731
-
Cancer statistics, 2014
-
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29.
-
(2014)
CA Cancer J Clin
, vol.64
, Issue.1
, pp. 9-29
-
-
Siegel, R.1
Ma, J.2
Zou, Z.3
Jemal, A.4
-
2
-
-
84879427246
-
Multimodality therapy for patients with high-risk prostate cancer: current status and future directions
-
Zaorsky NG, Trabulsi EJ, Lin J, Den RB. Multimodality therapy for patients with high-risk prostate cancer: current status and future directions. Semin Oncol 2013;40(3):308-321.
-
(2013)
Semin Oncol
, vol.40
, Issue.3
, pp. 308-321
-
-
Zaorsky, N.G.1
Trabulsi, E.J.2
Lin, J.3
Den, R.B.4
-
3
-
-
84880675653
-
Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials
-
Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol 2013;31(16):2029-2036.
-
(2013)
J Clin Oncol
, vol.31
, Issue.16
, pp. 2029-2036
-
-
Niraula, S.1
Le, L.W.2
Tannock, I.F.3
-
4
-
-
33644675811
-
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgenreceptor signaling axis
-
Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgenreceptor signaling axis. J Clin Oncol 2005;23(32):8253-8261.
-
(2005)
J Clin Oncol
, vol.23
, Issue.32
, pp. 8253-8261
-
-
Scher, H.I.1
Sawyers, C.L.2
-
5
-
-
77952554163
-
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
-
Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 2010;21(5):315-3124.
-
(2010)
Trends Endocrinol Metab
, vol.21
, Issue.5
, pp. 315-3124
-
-
Knudsen, K.E.1
Penning, T.M.2
-
6
-
-
79957443342
-
Abiraterone and increased survival in metastatic prostate cancer
-
de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005.
-
(2011)
N Engl J Med
, vol.364
, Issue.21
, pp. 1995-2005
-
-
de Bono, J.S.1
Logothetis, C.J.2
Molina, A.3
-
7
-
-
84872078210
-
Abiraterone in metastatic prostate cancer without previous chemotherapy
-
Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-148.
-
(2013)
N Engl J Med
, vol.368
, Issue.2
, pp. 138-148
-
-
Ryan, C.J.1
Smith, M.R.2
de Bono, J.S.3
-
8
-
-
84866770294
-
Increased survival with enzalutamide in prostate cancer after chemotherapy
-
Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-1197.
-
(2012)
N Engl J Med
, vol.367
, Issue.13
, pp. 1187-1197
-
-
Scher, H.I.1
Fizazi, K.2
Saad, F.3
-
9
-
-
77957682309
-
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
-
de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147-1154.
-
(2010)
Lancet
, vol.376
, Issue.9747
, pp. 1147-1154
-
-
de Bono, J.S.1
Oudard, S.2
Ozguroglu, M.3
-
10
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512.
-
(2004)
N Engl J Med
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.F.1
de Wit, R.2
Berry, W.R.3
-
11
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-422.
-
(2010)
N Engl J Med
, vol.363
, Issue.5
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
-
12
-
-
79958037582
-
Bone metastasis in prostate cancer: emerging therapeutic strategies
-
Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011;8(6):357-368.
-
(2011)
Nat Rev Clin Oncol
, vol.8
, Issue.6
, pp. 357-368
-
-
Sturge, J.1
Caley, M.P.2
Waxman, J.3
-
14
-
-
0028144689
-
Pain and its treatment in outpatients with metastatic cancer
-
Cleeland CS, Gonin R, Hatfield AK et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330(9):592-596.
-
(1994)
N Engl J Med
, vol.330
, Issue.9
, pp. 592-596
-
-
Cleeland, C.S.1
Gonin, R.2
Hatfield, A.K.3
-
15
-
-
0034085989
-
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients
-
Bubendorf L, Schopfer A, Wagner U et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31(5):578-583.
-
(2000)
Hum Pathol
, vol.31
, Issue.5
, pp. 578-583
-
-
Bubendorf, L.1
Schopfer, A.2
Wagner, U.3
-
16
-
-
0033017127
-
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer
-
Sabbatini P, Larson SM, Kremer A et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999;17(3):948-957.
-
(1999)
J Clin Oncol
, vol.17
, Issue.3
, pp. 948-957
-
-
Sabbatini, P.1
Larson, S.M.2
Kremer, A.3
-
17
-
-
0035125777
-
Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer
-
Turner SL, Gruenewald S, Spry N, Gebski V. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 2001;84(3):297-302.
-
(2001)
Br J Cancer
, vol.84
, Issue.3
, pp. 297-302
-
-
Turner, S.L.1
Gruenewald, S.2
Spry, N.3
Gebski, V.4
-
18
-
-
0027252452
-
Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer
-
Porter AT, McEwan AJ, Powe JE et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25(5):805-813.
-
(1993)
Int J Radiat Oncol Biol Phys
, vol.25
, Issue.5
, pp. 805-813
-
-
Porter, A.T.1
McEwan, A.J.2
Powe, J.E.3
-
19
-
-
0038503580
-
Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a doubleblind randomized study
-
Smeland S, Erikstein B, Aas M, Skovlund E, Hess SL, Fossa SD. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a doubleblind randomized study. Int J Radiat Oncol Biol Phys 2003;56(5): 1397-1404.
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.56
, Issue.5
, pp. 1397-1404
-
-
Smeland, S.1
Erikstein, B.2
Aas, M.3
Skovlund, E.4
Hess, S.L.5
Fossa, S.D.6
-
20
-
-
0142259750
-
Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group
-
Oosterhof GO, Roberts JT, de Reijke TM et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003;44(5):519-526.
-
(2003)
Eur Urol
, vol.44
, Issue.5
, pp. 519-526
-
-
Oosterhof, G.O.1
Roberts, J.T.2
de Reijke, T.M.3
-
21
-
-
0028233520
-
A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer
-
Quilty PM, Kirk D, Bolger JJ et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31(1):33-40.
-
(1994)
Radiother Oncol
, vol.31
, Issue.1
, pp. 33-40
-
-
Quilty, P.M.1
Kirk, D.2
Bolger, J.J.3
-
22
-
-
0036152138
-
Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial
-
Sciuto R, Festa A, Rea S et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002;43(1):79-86.
-
(2002)
J Nucl Med
, vol.43
, Issue.1
, pp. 79-86
-
-
Sciuto, R.1
Festa, A.2
Rea, S.3
-
23
-
-
0025781809
-
A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone
-
Lewington VJ, McEwan AJ, Ackery DM et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27(8):954-958.
-
(1991)
Eur J Cancer
, vol.27
, Issue.8
, pp. 954-958
-
-
Lewington, V.J.1
McEwan, A.J.2
Ackery, D.M.3
-
24
-
-
0031954325
-
Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial
-
Serafini AN, Houston SJ, Resche I et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16(4):1574-1581.
-
(1998)
J Clin Oncol
, vol.16
, Issue.4
, pp. 1574-1581
-
-
Serafini, A.N.1
Houston, S.J.2
Resche, I.3
-
25
-
-
2342509633
-
Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormonerefractory prostate cancer
-
Sartor O, Reid RH, Hoskin PJ et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormonerefractory prostate cancer. Urology 2004;63(5):940-945.
-
(2004)
Urology
, vol.63
, Issue.5
, pp. 940-945
-
-
Sartor, O.1
Reid, R.H.2
Hoskin, P.J.3
-
26
-
-
0031417685
-
A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases
-
Resche I, Chatal JF, Pecking A et al. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997;33(10):1583-1591.
-
(1997)
Eur J Cancer
, vol.33
, Issue.10
, pp. 1583-1591
-
-
Resche, I.1
Chatal, J.F.2
Pecking, A.3
-
27
-
-
0036733694
-
The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study
-
Han SH, de Klerk JM, Tan S et al. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002;43(9):1150-1156.
-
(2002)
J Nucl Med
, vol.43
, Issue.9
, pp. 1150-1156
-
-
Han, S.H.1
de Klerk, J.M.2
Tan, S.3
-
28
-
-
0025950294
-
Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo
-
Maxon HR, 3rd, Schroder LE, Hertzberg VS et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med 1991;32(10):1877-1881.
-
(1991)
J Nucl Med
, vol.32
, Issue.10
, pp. 1877-1881
-
-
Maxon, H.R.1
Schroder, L.E.2
Hertzberg, V.S.3
-
29
-
-
84874543674
-
Two-year survival followup of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castrationresistant prostate cancer and bone metastases
-
Nilsson S, Franzen L, Parker C et al. Two-year survival followup of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castrationresistant prostate cancer and bone metastases. Clin Genitourin Cancer 2013;11(1):20-26.
-
(2013)
Clin Genitourin Cancer
, vol.11
, Issue.1
, pp. 20-26
-
-
Nilsson, S.1
Franzen, L.2
Parker, C.3
-
30
-
-
20644447798
-
First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases
-
Nilsson S, Larsen RH, Fossa SD et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11(12):4451-4459.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.12
, pp. 4451-4459
-
-
Nilsson, S.1
Larsen, R.H.2
Fossa, S.D.3
-
31
-
-
84858706749
-
A randomized, doseresponse, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
-
Nilsson S, Strang P, Aksnes AK et al. A randomized, doseresponse, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012;48(5): 678-686.
-
(2012)
Eur J Cancer
, vol.48
, Issue.5
, pp. 678-686
-
-
Nilsson, S.1
Strang, P.2
Aksnes, A.K.3
-
32
-
-
84880428467
-
Alpha emitter radium-223 and survival in metastatic prostate cancer
-
Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(9):213-223.
-
(2013)
N Engl J Med
, vol.369
, Issue.9
, pp. 213-223
-
-
Parker, C.1
Nilsson, S.2
Heinrich, D.3
-
33
-
-
84871926771
-
A randomized, doubleblind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer
-
Parker CC, Pascoe S, Chodacki A et al. A randomized, doubleblind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 2013;63(2):189-197.
-
(2013)
Eur Urol
, vol.63
, Issue.2
, pp. 189-197
-
-
Parker, C.C.1
Pascoe, S.2
Chodacki, A.3
-
34
-
-
84867676607
-
Bone-targeted agents: preventing skeletal complications in prostate cancer
-
Morgans AK, Smith MR. Bone-targeted agents: preventing skeletal complications in prostate cancer. Urol Clin North Am 2012;39(4):533-546.
-
(2012)
Urol Clin North Am
, vol.39
, Issue.4
, pp. 533-546
-
-
Morgans, A.K.1
Smith, M.R.2
-
36
-
-
84871253334
-
Use of radionuclides in metastatic prostate cancer: pain relief and beyond
-
Vengalil S, O'Sullivan JM, Parker CC. Use of radionuclides in metastatic prostate cancer: pain relief and beyond. Curr Opin Support Palliat Care 2012;6(3):310-315.
-
(2012)
Curr Opin Support Palliat Care
, vol.6
, Issue.3
, pp. 310-315
-
-
Vengalil, S.1
O'Sullivan, J.M.2
Parker, C.C.3
-
37
-
-
0027491534
-
Strontium-89-precursor targeted therapy for pain relief of blastic metastatic disease
-
Robinson RG. Strontium-89-precursor targeted therapy for pain relief of blastic metastatic disease. Cancer 1993;72(11): 3433-3435.
-
(1993)
Cancer
, vol.72
, Issue.11
, pp. 3433-3435
-
-
Robinson, R.G.1
-
38
-
-
0022881267
-
Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate
-
Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986;12(9):447-454.
-
(1986)
Eur J Nucl Med
, vol.12
, Issue.9
, pp. 447-454
-
-
Blake, G.M.1
Zivanovic, M.A.2
McEwan, A.J.3
Ackery, D.M.4
-
39
-
-
19944386284
-
Radioisotopes for the palliation of metastatic bone cancer: a systematic review
-
Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005;6(6):392-400.
-
(2005)
Lancet Oncol
, vol.6
, Issue.6
, pp. 392-400
-
-
Finlay, I.G.1
Mason, M.D.2
Shelley, M.3
-
40
-
-
0024803298
-
A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases
-
Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale AA. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol 1989;7(12): 1926-1931.
-
(1989)
J Clin Oncol
, vol.7
, Issue.12
, pp. 1926-1931
-
-
Turner, J.H.1
Claringbold, P.G.2
Hetherington, E.L.3
Sorby, P.4
Martindale, A.A.5
-
41
-
-
11244281049
-
The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain
-
Liepe K, Runge R, Kotzerke J. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol 2005;131(1):60-66.
-
(2005)
J Cancer Res Clin Oncol
, vol.131
, Issue.1
, pp. 60-66
-
-
Liepe, K.1
Runge, R.2
Kotzerke, J.3
-
42
-
-
34447545672
-
A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases
-
Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 2007;28(8): 623-630.
-
(2007)
Nucl Med Commun
, vol.28
, Issue.8
, pp. 623-630
-
-
Liepe, K.1
Kotzerke, J.2
-
43
-
-
34247636849
-
89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma
-
Baczyk M, Czepczynski R, Milecki P, Pisarek M, Oleksa R, Sowinski J. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun 2007;28(4):245-250.
-
(2007)
Nucl Med Commun
, vol.28
, Issue.4
, pp. 245-250
-
-
Baczyk, M.1
Czepczynski, R.2
Milecki, P.3
Pisarek, M.4
Oleksa, R.5
Sowinski, J.6
-
44
-
-
33746707858
-
High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
-
Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 2006;12(20 Pt 2):6250s-6257s.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.20
, pp. 6250s-6257s
-
-
Bruland, O.S.1
Nilsson, S.2
Fisher, D.R.3
Larsen, R.H.4
-
45
-
-
34347244905
-
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
-
Nilsson S, Franzen L, Parker C et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8(7):587-594.
-
(2007)
Lancet Oncol
, vol.8
, Issue.7
, pp. 587-594
-
-
Nilsson, S.1
Franzen, L.2
Parker, C.3
|